Headlines

MTI investee Ai2 wins first commercial contract

1 September 2010
Ai2 Limited, a medical materials coating spin-out from the University of Manchester, has announced the signing of a joint development and licensing agreement with UK based Sauflon Pharmaceuticals Ltd, a privately owned pharmaceutical company which specialises in a number of ophthalmic product areas. This deal represents Ai2’s first major commercial contract.
Read

MTI increases investment in UPF Investee, in Arvia Technology

1 May 2010
MTI Partners has announced the investment of £250,000 in Arvia Technology, an award winning North West based Global Cleantech 100 company, as a first part of a substantial investment round expected to reach £750,000.
Read

MTI Leads £1.15m Investment Round in PowerOasis

1 May 2010
MTI Partners has announced the investment of £650,000 from its UMIP Premier Fund (UPF) as part of a £1.15m investment round in Swindon based, intelligent telecoms power solutions provider, PowerOasis.
Read

MTI Invest in University of Manchester med-tech spin-out, BiOxyDyn

1 May 2010
Manchester based hi-tech investment specialists, MTI Partners, has announced a UPF (the UMIP Premier Fund) investment, in University of Manchester med-tech spin-out BiOxyDyn.
Read

MTI Portfolio Company APATECH sold for $330 million

1 March 2010
MTI, the leading UK technology venture capital investor, today announces its most successful ever exit with the sale of portfolio company APATECH to US healthcare group Baxter International Inc. for total consideration of up to USD330 million.
Read

MTI leads £2m investment round to help bring new pest control products to market

1 February 2010
Hi-tech specialists, MTI Partners, has announced the investment of £1m from their UPF fund as part of a £2m investment in EXOSECT, a UK developer of environmentally-friendly pest control products, to help bring new products to market across the UK, Europe and the US.
Read

MTI investee MYCONOSTICA launches Pneumocystis diagnostic kit in Europe and Canada

1 January 2010
MTI investee Myconostica Ltd, a UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces that it has launched a new version of its of MycAssay™ Pneumocystis product in the European Community and Canada.
Read

NWDA awards £9m Transitional fund to MTI

1 January 2010
North West hi-tech investment specialists, MTI Partners, have announced that with YFM they have successfully secured a £9 million fund management mandate from the Northwest Regional Development Agency (NWDA).
Read